Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
SI-BONE heads into its November 9 earnings date with short sellers retreating, analyst conviction building, and the stock sitting 28% below the Street's mean price target.
The sharpest signal this week came from the analyst desk. Truist Securities raised its price target on SIBN to $25 from $23 today, keeping its Buy rating, the latest in a string of upward revisions since the August earnings beat. UBS and TD Cowen both lifted targets after that Q2 print as well, with UBS anchoring at $25. The consensus mean of $25.22 implies roughly 28% upside from the current $19.68 close. Bulls point to a 12% year-on-year revenue gain in the most recent quarter, 79.8% gross margins, 1,650 active physicians, and a pipeline of near-term catalysts: the Smith and Nephew partnership, a third breakthrough-device designation expected in Q4, and potential reimbursement tailwinds from the FY27 IPPS proposal. Bears counter that the company is a single-anatomy play with no profits yet, the PE sits at negative 57 times, and the EV/EBITDA multiple at 41 times has contracted about 2.4 points over the past 30 days. EPS momentum factor scores rank in the 7th to 17th percentile, a reminder that forward estimates have drifted lower through the year even as revenue surprises have been positive.
Short positioning has eased materially, and the borrow market is far from stressed. Short interest has dropped 8.6% over the past week to roughly 12% of free float, down from levels closer to 13% earlier in the month. That remains an elevated absolute level, but the direction of travel is decidedly toward covering rather than building. Borrow costs reflect no squeeze pressure at all: the cost to borrow stands at 0.58%, barely above the one-month average and comfortably in the "low" range. Availability is ample, at 382% of short interest, meaning there are nearly four shares available in the lending pool for every share already borrowed, well above the 52-week tightest reading of 368%. The ORTEX short score of 66.5 is elevated in absolute terms but has eased from an intraweek peak near 68.4 on October 1, consistent with the reduction in shares short. Options traders show no alarm either: the put/call ratio of 0.21 is fractionally above its 20-day mean and well below any historic defensive reading, suggesting options positioning is neutral rather than cautious.
Ownership is worth noting for one reason: First Light Asset Management has become a dominant force in the register, holding 18.1% of shares as of June 30, and founder-linked filing by Mathew P. Arens, reflecting 18.36% of the class as of May, shows concentrated insider-adjacent ownership at the top. Cadian Capital Management built a fresh 7.5% stake disclosed in August. BlackRock added shares to reach 8% as of July. Against that backdrop, recent insider sells look modest in context: the CFO Anshul Maheshwari sold small tranches totalling under $100,000 in early October under a pre-arranged 10b5-1 plan, which markets routine rather than discretionary. Director Jeffrey Dunn exercised options and sold 20,000 shares on October 1 for $369,400, but the exercise itself was at $4.68, a compensation mechanic rather than a directional bet. Net insider activity over 90 days is negative $3.9 million, but the bulk of that reflects option exercises and planned sales rather than open-market conviction selling.
The last earnings print in August produced a 3.8% one-day gain and a 6.1% five-day move, both positive, suggesting the market has rewarded recent results. The November 9 report covers a quarter that will test whether the company's conservative guidance, set after Q1 and Q2 beats, holds up again. The most correlated peer, KIDS (OrthoPediatrics) fell 3.4% on the week while ZBH and SYK managed gains of 2.7% and 1.6% respectively, a mixed read on broad med-tech sentiment heading into the October reporting season.
With short sellers reducing exposure, analyst targets clustering above $25, and earnings 26 days away, the key question is whether the next quarterly print repeats the beat-and-raise cadence that has driven target upgrades throughout 2026, or whether EPS momentum, still pointing lower in factor rankings, begins to weigh on the Street's patience.
See the live data behind this article on ORTEX.
Open SIBN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
